BioCentury
ARTICLE | Clinical News

KB004: Phase I started

March 28, 2011 7:00 AM UTC

KaloBios began an open-label, dose-escalation, U.S. Phase I trial to evaluate weekly 20, 70, 200 and 700 mg IV KB004 in a 21-day cycle for up to 17 cycles in up to 24 patients. Following the dose-esca...